Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

α-Synuclein in Lewy bodies

Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · see citing works

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · see citing works

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium

McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works

α-Synuclein Locus Triplication Causes Parkinson's Disease

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · see citing works

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop

McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · see citing works

Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy

Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · see citing works

Levodopa and the Progression of Parkinson's Disease

The Parkinson Study Group (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,844 · see citing works

Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · see citing works

Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System

Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722 · see citing works

Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy

Conway, K. A., Lee, S., Rochet, J., Ding, T. T., Williamson, R. E., & Lansbury, P. T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.571 · Cited by 1,543 · see citing works

Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease

Anderson, J. P., Walker, D., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,418 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works

Active Caspase-1 Is a Regulator of Unconventional Protein Secretion

Keller, M., Rüegg, A., Werner, S., & Beer, H. (2008) · Cell · doi:10.1016/j.cell.2007.12.040 · Cited by 851 · see citing works

Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology

Outeiro, T. F., & Lindquist, S. L. (2003) · Science · doi:10.1126/science.1090439 · Cited by 808 · see citing works

Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates

Lee, H.-J., Patel, S. S., & Lee, S. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0692-05.2005 · Cited by 798 · see citing works

Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715 · see citing works

Genetics of Parkinson disease: paradigm shifts and future prospects

Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 709 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

THE BIOCHEMISTRY OF PARKINSON'S DISEASE

Cookson, M. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133400 · Cited by 659 · see citing works

Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · see citing works

α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma

El-Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Cooper, L. J., Fullwood, N. J., Gibson, M. J., Curran, M. D., Court, J. A., Mann, D. M. A., Ikeda, S.-I., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0098fje · Cited by 590 · see citing works

Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies

Kramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571 · see citing works

Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death

Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D. L., & Greene, L. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09549.2001 · Cited by 569 · see citing works

Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T. A., Diep, L., Fox, M., Goldstein, J. M., Soriano, F., Seubert, P. A., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112832 · Cited by 527 · see citing works

Molecular markers of early Parkinson's disease based on gene expression in blood

Scherzer, C. R., Eklund, A. C., Morse, L. J., Liao, Z., Locascio, J. J., Fefer, D., Schwarzschild, M. A., Schlossmacher, M. G., Hauser, M. A., Vance, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610204104 · Cited by 511 · see citing works

Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease

Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works

Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication

Fuchs, J., Nilsson, C., Kachergus, J. M., Munz, M., Larsson, E., Schüle, B., Langston, J. W., Middleton, F. A., Ross, O. A., Hulihan, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000254458.17630.c5 · Cited by 397 · see citing works

Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments

El‐Agnaf, O. M. A., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., & Wallace, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01418-5 · Cited by 363 · see citing works

α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication

Miller, D. W., Hague, S., Clarimón, J., Baptista, M., Gwinn, K. A., Cookson, M., & Singleton, A. (2004) · Neurology · doi:10.1212/01.wnl.0000127517.33208.f4 · Cited by 356 · see citing works

Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics

Reiber, H. (2003) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2003-00229 · Cited by 351 · see citing works

Neuropathological spectrum of synucleinopathies

Jellinger, K. A. (2003) · Movement Disorders · doi:10.1002/mds.10557 · Cited by 338 · see citing works

The Co-chaperone Carboxyl Terminus of Hsp70-interacting Protein (CHIP) Mediates α-Synuclein Degradation Decisions between Proteasomal and Lysosomal Pathways

Shin, Y., Klucken, J., Patterson, C., Hyman, B. T., & McLean, P. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503326200 · Cited by 328 · see citing works

Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease

Nishioka, K., Hayashi, S., Farrer, M. J., Singleton, A., Yoshino, H., Imai, H., Kitami, T., Sato, K., Kuroda, R., Tomiyama, H., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20753 · Cited by 315 · see citing works

Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo

Periquet, M., Fulga, T. A., Myllykangas, L., Schlossmacher, M. G., & Feany, M. Β. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0285-07.2007 · Cited by 291 · see citing works

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz‐Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289 · see citing works

Molecular Crowding Accelerates Fibrillization of α-Synuclein: Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's Disease?

Shtilerman, M. D., Ding, T. T., & Lansbury, P. T. (2002) · Biochemistry · doi:10.1021/bi0120906 · Cited by 280 · see citing works

Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain

Fuchs, J., Tichopád, A., Golub, Y., Munz, M., Schweitzer, K. J., Wolf, B., Berg, D., Mueller, J. C., & Gasser, T. (2007) · The FASEB Journal · doi:10.1096/fj.07-9348com · Cited by 247 · see citing works

Multiple-system atrophy: a new α-synuclein disease?

Gai, W., Power, J., Blumbergs, P. C., & Blessing, W. W. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79256-4 · Cited by 229 · see citing works

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease

Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228 · see citing works

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H., Sparbier, K., Av, S., Cepek, L., Trenkwalder, C., Rüther, E., et al. (2006) · Brain · doi:10.1093/brain/awl063 · Cited by 209 · see citing works

In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease?

Chesselet, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.08.006 · Cited by 186 · see citing works

Biomarkers and Parkinson's disease

Michell, A. W. (2004) · Brain · doi:10.1093/brain/awh198 · Cited by 183 · see citing works

Cell systems and the toxic mechanism(s) of α-synuclein

Cookson, M., & van der Brug, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.022 · Cited by 173 · see citing works

The genetics of Parkinson disease: implications for neurological care

Klein, C., & Schlossmacher, M. G. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0126 · Cited by 169 · see citing works

Tumors of the choroid plexus

Rickert, C. H., & Paulus, W. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010101)52:1 · Cited by 160 · see citing works

Plasma α-synuclein is decreased in subjects with Parkinson's disease

Li, Q., Mok, S. S., Laughton, K. M., McLean, C., Cappai, R., Masters, C. L., Culvenor, J. G., & Horne, M. K. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.006 · Cited by 160 · see citing works

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides

Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 143 · see citing works

What brown cannot do for you

Rimm, D. L. (2006) · Nature Biotechnology · doi:10.1038/nbt0806-914 · Cited by 139 · see citing works

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehütte, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 131 · see citing works

Biomarker method validation in anticancer drug development

Cummings, J., Ward, T. H., Greystoke, A., Ranson, M., & Dive, C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707441 · Cited by 131 · see citing works

Accuracy in the clinical diagnosis of parkinsonian syndromes

Gibb, W. R. G. (1988) · Postgraduate Medical Journal · doi:10.1136/pgmj.64.751.345 · Cited by 101 · see citing works

Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein

Wadsworth, J. D. F. (2006) · Brain · doi:10.1093/brain/awl076 · Cited by 99 · see citing works

Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

Mollenhauer, B., Cepek, L., Bibl, M., Wiltfang, J., Schulz‐Schaeffer, W., Ciesielczyk, B., Neumann, M., Steinacker, P., Kretzschmar, H. A., Poser, S., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083178 · Cited by 83 · see citing works

Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies

Mollenhauer, B., Bibl, M., Wiltfang, J., Steinacker, P., Ciesielczyk, B., Neubert, K., Trenkwalder, C., & Otto, M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.035 · Cited by 72 · see citing works

Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease

Mollenhauer, B., Bibl, M., Trenkwalder, C., Stiens, G., Cepek, L., Steinacker, P., Ciesielczyk, B., Neubert, K., Wiltfang, J., Kretzschmar, H. A., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0235-7 · Cited by 68 · see citing works

Platelet α- and γ-synucleins in Parkinson's disease and normal control subjects

Li, Q.-X., Campbell, B. C. V., McLean, C., Thyagarajan, D., Gai, W.-P., Kapsa, R. M. I., Beyreuther, K. T., Masters, C. L., & Culvenor, J. G. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4406 · Cited by 49 · see citing works

Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms

Halliday, G. M., & McCann, H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.006 · Cited by 48 · see citing works

Determination of α‐synuclein concentration in human plasma using ELISA

Fjorback, W. A., Varming, K., & Jensen, H. P. (2007) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601161497 · Cited by 46 · see citing works

A more efficient enzyme-linked immunosorbent assay for measurement of α-synuclein in cerebrospinal fluid

van Geel, W. J. A., Abdo, W. F., Melis, R. J. F., Williams, S., Bloem, B. R., & Verbeek, M. M. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.09.021 · Cited by 32 · see citing works

Biomarkers in Parkinson’s disease

Dorsey, E. R., Holloway, R. G., & Ravina, B. M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.823 · Cited by 23 · see citing works

Diagnostic problems during late course in Creutzfeldt-Jakob disease

Mollenhauer, B., Serafin, S., Zerr, I., Steinhoff, B. J., Otto, M., Scherer, M., Schulz‐Schaeffer, W., & Poser, S. (2003) · Journal of Neurology · doi:10.1007/s00415-003-1059-3 · Cited by 20 · see citing works

Parkinson's Disease: Assays for the Ubiquitin Ligase Activity of Neural Parkin

Schlossmacher, M. G., & Shimura, H. (2005) · Humana Press eBooks · doi:10.1385/1-59259-895-1:351 · Cited by 19 · see citing works

-Synuclein in Parkinson's Disease

Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · see citing works

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

Irwin, D. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3549 · Cited by 875 · see citing works

Exosomal cell-to-cell transmission of alpha synuclein oligomers

Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal‐Getkin, O., Winslow, A. R., Zhu, L., Vanderburg, C. R., & McLean, P. J. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-42 · Cited by 852 · see citing works

Dementia with Lewy bodies.

McKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756 · see citing works

Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease

Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676 · see citing works

Protein transmission in neurodegenerative disease

Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625 · see citing works

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

Mollenhauer, B., Locascio, J. J., Schulz‐Schaeffer, W., Sixel‐Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 623 · see citing works

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works

Alpha‐synuclein <scp>RT</scp> ‐Qu <scp>IC</scp> in the <scp>CSF</scp> of patients with alpha‐synucleinopathies

Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608 · see citing works

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works

Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease

Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El‐Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 526 · see citing works

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418 · see citing works

α-synuclein in the pathophysiology of Alzheimer’s disease

Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works

Research in motion: the enigma of Parkinson's disease pathology spread

Brundin, P., Li, J., Holton, J. L., Lindvall, O., & Révész, T. (2008) · Nature reviews. Neuroscience · doi:10.1038/nrn2477 · Cited by 328 · see citing works

Multiple system atrophy: A primary oligodendrogliopathy

Wenning, G. K., Stefanova, N., Jellinger, K. A., Poewe, W. H., & Schlossmacher, M. G. (2008) · Annals of Neurology · doi:10.1002/ana.21465 · Cited by 320 · see citing works

Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity

Danzer, K. M., Ruf, W. P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C. C., Hyman, B. T., & McLean, P. J. (2010) · The FASEB Journal · doi:10.1096/fj.10-164624 · Cited by 309 · see citing works

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramı́rez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 308 · see citing works

Acid β‐glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α‐synuclein processing

Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I. L., Säftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303 · see citing works

Phosphorylated α-Synuclein in Parkinson’s Disease

Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. ‐., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 281 · see citing works

Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo

Cullen, V., Lindfors, M., Ng, J., Paetau, A. E., Swinton, E., Kolodziej, P., Boston, H., Säftig, P., Woulfe, J., Feany, M. Β., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-5 · Cited by 277 · see citing works

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265 · see citing works

GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein

Scherzer, C. R., Grass, J. A., Liao, Z., Pepivani, I., Zheng, B., Eklund, A. C., Ney, P. A., Ng, J., McGoldrick, M., Mollenhauer, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802437105 · Cited by 271 · see citing works

Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease

Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., Carlo, C. D., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 268 · see citing works

CSF biomarkers and clinical progression of Parkinson disease

Hall, S., Surova, Y., Öhrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2014) · Neurology · doi:10.1212/wnl.0000000000001098 · Cited by 236 · see citing works

Detection of neuron-derived pathological α-synuclein in blood

Kluge, A., Bunk, J., Schaeffer, E., Drobny, A., Xiang, W., Knacke, H., Bub, S., Lückstädt, W., Arnold, P., Lucius, R., et al. (2022) · Brain · doi:10.1093/brain/awac115 · Cited by 227 · see citing works

Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis

Eusebi, P., Giannandrea, D., Biscetti, L., Abraha, I., Chiasserini, D., Orso, M., Calabresi, P., & Parnetti, L. (2017) · Movement Disorders · doi:10.1002/mds.27110 · Cited by 222 · see citing works

Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease

Shi, M. Y., Zabetian, C. P., Hancock, A. M., Ginghină, C., Hong, Z., Yearout, D., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D. R., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.009 · Cited by 219 · see citing works

Alpha synuclein is transported into and out of the brain by the blood-brain barrier

Sui, Y.-T., Bullock, K. M., Erickson, M. A., Zhang, J., & Banks, W. A. (2014) · Peptides · doi:10.1016/j.peptides.2014.09.018 · Cited by 212 · see citing works

Mild Cognitive Impairment in Parkinson’s Disease

Aarsland, D., Brønnick, K., & Fladby, T. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0203-1 · Cited by 213 · see citing works

Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies

Schmid, A. W., Fauvet, B., Moniatte, M., & Lashuel, H. A. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r113.032730 · Cited by 212 · see citing works

Cerebrospinal fluid biomarkers in Parkinson disease

Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209 · see citing works

Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy

Jellinger, K. A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170397 · Cited by 209 · see citing works

Phosphorylated α‐synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease

Foulds, P. G., Mitchell, J. D., Parker, A., Turner, R., Green, G., Diggle, P. J., Hasegawa, M., Taylor, M., Mann, D. M. A., & Allsop, D. (2011) · The FASEB Journal · doi:10.1096/fj.10-179192 · Cited by 207 · see citing works

Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation

Tong, J., Wong, H., Guttman, M., Ang, L. C., Forno, L. S., Shimadzu, M., Rajput, A. H., Muenter, M. D., Kish, S. J., Hornykiewicz, O., et al. (2009) · Brain · doi:10.1093/brain/awp282 · Cited by 204 · see citing works

Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

Gao, L., Tang, H., Nie, K., Wang, L., Zhao, J., Gan, R., Huang, J., Zhu, R., Feng, S., Duan, Z., et al. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.961454 · Cited by 204 · see citing works

Glia and alpha-synuclein in neurodegeneration: A complex interaction

Brück, D., Wenning, G. K., Stefanova, N., & Fellner, L. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.003 · Cited by 202 · see citing works

Cognitive and Behavioral Neurology

Finger, E. C., & Daffner, K. R. (2011) · Springer eBooks · doi:10.1007/978-0-387-88555-1_8 · Cited by 200 · see citing works

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 198 · see citing works

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease

Park, M., Cheon, S., Bae, H.-R., Kim, S.-H., & Kim, J. W. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.4.215 · Cited by 195 · see citing works

A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease

Foulds, P. G., Diggle, P. J., Mitchell, J. D., Parker, A., Hasegawa, M., Masuda‐Suzukake, M., Mann, D. M. A., & Allsop, D. (2013) · Scientific Reports · doi:10.1038/srep02540 · Cited by 186 · see citing works

Fluid Biomarkers for Synaptic Dysfunction and Loss

Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works

Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

Han, M. C., Nagele, E. P., DeMarshall, C. A., Acharya, N. K., & Nagele, R. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032383 · Cited by 175 · see citing works

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

Perrin, R. J., Craig‐Schapiro, R., Malone, J. P., Shah, A. R., Erdmann-Gilmore, P., Davis, A., Roe, C. M., Peskind, E. R., Li, G., Galasko, D. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016032 · Cited by 172 · see citing works

α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171 · see citing works

Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias

Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., Carlo, C. D., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 170 · see citing works

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Oliveira, L. M. A., Gasser, T., Edwards, R. H., Zweckstetter, M., Melki, R., Stefanis, L., Lashuel, H. A., Sulzer, D. L., Vekrellis, K., Halliday, G. M., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00203-9 · Cited by 169 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167 · see citing works

L ongitudinal M easurements of C erebrospinal F luid B iomarkers in P arkinson's D isease

Hall, S., Surova, Y., Öhrfelt, A., Study, T. S. B., Blennow, K., Zetterberg, H., & Hansson, O. (2016) · Movement Disorders · doi:10.1002/mds.26578 · Cited by 165 · see citing works

Assessment of α-Synuclein Secretion in Mouse and Human Brain Parenchyma

Emmanouilidou, E., Elenis, D., Papasilekas, T., Stranjalis, G., Gerozissis, K., Ioannou, P. C., & Vekrellis, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022225 · Cited by 163 · see citing works

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works

Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies

Magalhães, P., & Lashuel, H. A. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00357-0 · Cited by 157 · see citing works

Biomarkers in dementia: clinical utility and new directions

Ahmed, R. M., Paterson, R. W., Warren, J. D., Zetterberg, H., O'Brien, J. T., Fox, N. C., Halliday, G. M., & Schott, J. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307662 · Cited by 155 · see citing works

Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity

Xiang, W., Schlachetzki, J. C. M., Helling, S., Bussmann, J., Berlinghof, M., Schäffer, T. E., Marcus, K., Winkler, J., Klucken, J., & Becker, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.01.004 · Cited by 152 · see citing works

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

Mollenhauer, B., Caspell‐Garcia, C., Coffey, C. S., Taylor, P., Shaw, L. M. J., Trojanowski, J. Q., Singleton, A. B., Frasier, M. A., Marek, K., Galasko, D. R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004609 · Cited by 153 · see citing works

Papp–Lantos inclusions and the pathogenesis of multiple system atrophy: an update

Jellinger, K. A., & Lantos, P. L. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0672-3 · Cited by 144 · see citing works

Differential levels of -synuclein, -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

Kasuga, K., Tokutake, T., Ishikawa, A., Uchiyama, T., Tokuda, T., Onodera, O., Nishizawa, M., & Ikeuchi, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.197483 · Cited by 142 · see citing works

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., Hansson, O., & Nielsen, H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053250 · Cited by 141 · see citing works

The spectrum of cognitive impairment in Lewy body diseases

Goldman, J. G., Williams‐Gray, C. H., Barker, R. A., Duda, J. E., & Galvin, J. E. (2014) · Movement Disorders · doi:10.1002/mds.25866 · Cited by 142 · see citing works

Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort

Stewart, T., Liu, C., Ginghină, C., Cain, K. C., Auinger, P., Cholerton, B., Shi, M. Y., & Zhang, J. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.12.007 · Cited by 140 · see citing works

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 139 · see citing works

Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies

Brás, I. C., & Outeiro, T. F. (2021) · Cells · doi:10.3390/cells10020375 · Cited by 136 · see citing works

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

Lindström, V., Fagerqvist, T., Nordström, E. K. L., Eriksson, F., Lord, A., Tucker, S. M., Andersson, J., Johannesson, M., Schell, H., Kahle, P. J., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.009 · Cited by 135 · see citing works

Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies

Oeckl, P., Metzger, F., Nagl, M., Arnim, C. A. F. V., Halbgebauer, S., Steinacker, P., Ludolph, A. C., & Otto, M. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.059915 · Cited by 135 · see citing works

Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough

Ganguly, U., Singh, S., Pal, S., Prasad, S., Agrawal, B. K., Saini, R. V., & Chakrabarti, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.702639 · Cited by 132 · see citing works

CSF α-synuclein does not differentiate between parkinsonian disorders

Aerts, M., Esselink, R. A. J., Abdo, W. F., Bloem, B. R., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.001 · Cited by 126 · see citing works

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease

Tian, C., Liu, G., Gao, L., Soltys, D., Pan, C., Stewart, T., Shi, M. Y., Xie, Z., Liu, N., Feng, T., et al. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0155-y · Cited by 122 · see citing works

Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease &amp; Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121 · see citing works

Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease

Agbo, D. B., Wolf, E., Jessen, F., Oechsner, M., Hametner, E., Poewe, W. H., Reindl, M., Oertel, W. H., Noelker, C., Bacher, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b90d1 · Cited by 120 · see citing works

Quantification of α-Synuclein in Cerebrospinal Fluid As a Biomarker Candidate: Review of the Literature and Considerations for Future Studies

Mollenhauer, B., El‐Agnaf, O. M. A., Marcus, K., Trenkwalder, C., & Schlossmacher, M. G. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.90 · Cited by 114 · see citing works

Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids

Horrocks, M. H., Lee, S. F., Gandhi, S., Magdalinou, N. K., Chen, S. W., Devine, M. J., Tosatto, L., Kjærgaard, M., Beckwith, J. S., Zetterberg, H., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00324 · Cited by 113 · see citing works

Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method

Öhrfelt, A., Zetterberg, H., Andersson, K., Persson, R., Secic, D., Brinkmalm, G., Wallin, A., Mulugeta, E., Francis, P. T., Vanmechelen, E., et al. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0527-x · Cited by 109 · see citing works

The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson’s disease

Vargas, J., Grudina, C., & Zurzolo, C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.012 · Cited by 106 · see citing works

Expansion of the Parkinson disease-associated SNCA- Rep1 allele upregulates human α-synuclein in transgenic mouse brain

Cronin, K. D., Ge, D., Manninger, P., Linnertz, C. L., Rossoshek, A., Orrison, B. M., Bernard, D. J., El‐Agnaf, O. M. A., Schlossmacher, M. G., Nussbaum, R. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp265 · Cited by 109 · see citing works

α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK 2‐linked Parkinson's disease

Garrido, A., Fairfoul, G., TOLOSA, E. S., Martı́, M. J., Green, A. J. E., & the Barcelona LRRK2 Study Group (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.772 · Cited by 108 · see citing works

Altered CSF Orexin and α-Synuclein Levels in Dementia Patients

Wennström, M., Londos, E., Minthon, L., & Nielsen, H. M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111655 · Cited by 104 · see citing works

One-step nanoscale expansion microscopy reveals individual protein shapes

Shaib, A. H., Chouaib, A. A., Chowdhury, R., Altendorf, J., Mihaylov, D., Zhang, C., Krah, D., Imani, V., Spencer, R. K. W., Georgiev, S. V., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02431-9 · Cited by 104 · see citing works

Dementia with Lewy Bodies

Weisman, D., & McKeith, I. G. (2007) · Seminars in Neurology · doi:10.1055/s-2006-956754 · Cited by 103 · see citing works

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies

Foulds, P. G., Yokota, O., Thurston, A., Davidson, Y. S., Ahmed, Z., Holton, J. L., Thompson, J. C., Akiyama, H., Arai, T., Hasegawa, M., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.003 · Cited by 101 · see citing works

Biomarkers in dementia with Lewy bodies: a review

Sinha, N., Firbank, M., & O'Brien, J. T. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2749 · Cited by 98 · see citing works

Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation

Roodveldt, C., Labrador‐Garrido, A., González‐Rey, E., Lachaud, C. C., Guilliams, T., Fernández-Montesinos, R., Benitez-Rondan, A., Robledo, G., Hmadcha, A., Delgado, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079160 · Cited by 96 · see citing works

Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease

Shim, K. H., Kang, M. J., Youn, Y. C., An, S. S. A., & Kim, S. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01150-0 · Cited by 98 · see citing works

CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders

Mondello, S., Constantinescu, R., Zetterberg, H., Andréasson, U., Holmberg, B., & Jeromin, A. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.01.011 · Cited by 98 · see citing works

α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works

The Utility of α-Synuclein as Biofluid Marker in Neurodegenerative Diseases: a Systematic Review of The Literature

Simonsen, A. H., Kuiperij, H. B., El‐Agnaf, O. M. A., Engelborghs, S., Herukka, S., Parnetti, L., Rektorová, I., Vanmechelen, E., Kapaki, E. N., Verbeek, M. M., et al. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.105 · Cited by 94 · see citing works

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83 · see citing works

Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions

Magdalinou, N. K., Lees, A. J., & Zetterberg, H. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307539 · Cited by 93 · see citing works

CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

Noguchi‐Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., El‐Agnaf, O. M. A., & Yamada, M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.055 · Cited by 92 · see citing works

Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease

Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., McCluskey, L. F., Elman, L. B., Karlawish, J. H., Hurtig, H. I., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0723-9 · Cited by 90 · see citing works

The robust electrochemical detection of a Parkinson's disease marker in whole blood sera

Bryan, T., Luo, X., Forsgren, L., Morozova‐Roche, L. A., & Davis, J. J. (2012) · Chemical Science · doi:10.1039/c2sc21221h · Cited by 88 · see citing works

The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death

Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 85 · see citing works

Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients

Swanson, C. R., Berlyand, Y., Xie, S. X., Alcalay, R. N., Chahine, L. M., & Chen‐Plotkin, A. S. (2015) · Movement Disorders · doi:10.1002/mds.26290 · Cited by 86 · see citing works

Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders

Manzanza, N. D. O., Sedlackova, L., & Kalaria, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690293 · Cited by 89 · see citing works

Monoclonal antibodies selective for α‐synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α‐synuclein transgenic mice with the disease‐causing A30P mutation

Fagerqvist, T., Lindström, V., Nordström, E. K. L., Lord, A., Tucker, S. M., Su, X., Sahlin, C., Kasrayan, A., Andersson, J., Welander, H., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12175 · Cited by 86 · see citing works

Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative

Laurens, B., Constantinescu, R., Freeman, R. L., Gerhard, A., Jellinger, K. A., Jeromin, A., Krismer, F., Mollenhauer, B., Schlossmacher, M. G., Shaw, L. M. J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.004 · Cited by 85 · see citing works

Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels

Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85 · see citing works

The phosphorylation of α‐synuclein: development and implication for the mechanism and therapy of the Parkinson's disease

Xu, Y., Deng, Y., & Qing, H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13234 · Cited by 82 · see citing works

CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes

Constantinides, V. C., Paraskevas, G. P., Emmanouilidou, E., Petropoulou, O., Bougea, A. M., Vekrellis, K., Evdokimidis, I., Stamboulis, E., & Kapaki, E. N. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.09.039 · Cited by 80 · see citing works

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease

Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78 · see citing works

S5‐01‐05: Quantification of total α‐synuclein in cerebrospinal fluid by ELISA: Cross‐sectional investigation of subjects with dementia and parkinsonism

Schlossmacher, M. G. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.574

Validation of a new assay for α-synuclein detection in cerebrospinal fluid

Førland, M. G. G., Öhrfelt, A., Oftedal, L., Tysnes, O., Larsen, J. P., Blennow, K., Zetterberg, H., Alves, G. W., & Lange, J. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0409 · Cited by 9 · see citing works

Validation of a new assay for alpha-synuclein detection in cerebrospinal fluid

Forland, M., Öhrfelt, A., Oftedal, L., Tysnes, O., Larsen, J., Blennow, K., Zetterberg, H., Alves, G., & Lange, J. (2017) · UCL Discovery (University College London)

P1‐358: A novel, highly sensitive and specific enyzme‐linked immunosorbent assay (ELISA) for the measurement of total human alpha‐synuclein in plasma and cerebrospinal fluid

Koehler, N. K. U., Stransky, E., Ruf, K., Laske, C., Richartz, E., Batra, A., & Buchkremer, G. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.940

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 139 · see citing works